JS-007
- Generic Name
- JS-007
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06954467
- Locations
- 🇨🇳
The First Affiliated Hospital of USTC, Hefei, Anhui, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Phase 1
Not yet recruiting
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 117
- Registration Number
- NCT06370754
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath